Advertisement


David Raben, MD, on NSCLC: Results From the PACIFIC Trial

2018 ASTRO Annual Meeting

Advertisement

David Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA10).



Related Videos

Head and Neck Cancer
Symptom Management

Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity

Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with dein...

Issues in Oncology

Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy

Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival comp...

Prostate Cancer

Alan Pollack, MD, on Prostate Cancer: Results From the SPPORT Trial

Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–...

Prostate Cancer

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment...

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation an...

Advertisement

Advertisement



Advertisement